JECX.JK
SellFallen FavouritePT Nitrasanata Dharma · Healthcare · Indonesia · $244M cap · $219K/day traded
IDR 970 -6.3% · close 2 Nov · scored 3 Nov
StockRank up 8.1 since 31 Oct: Value up 7 as the price fell 6%, Quality up 6.
Fallen Favourite: A good business, still expensive, and its momentum is weak.
As of 3 Nov 2026, MoatMap's StockRank for PT Nitrasanata Dharma (JECX.JK) is 33/100, ranked against 24,000+ stocks in 35 markets (Quality 64, Value 35, Momentum 23, each scored against its sector).
Does StockRank work? Each month we publish how each tenth of the ranking did, whichever way it went. See the record →
ABOUT PT NITRASANATA DHARMA
Read
PT Nitrasanata Dharma operates as a provider of eye health services in Indonesia. The company provides ophthalmic services including cataract, lens and refractive surgery, glaucoma treatment, retina care, okuloplasty and orbital reconstruction, pediatric ophthalmology and strabismus management,...
FINANCIAL SUMMARY (IDR)
| Year | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|
| Revenue | 825.1B | 887.7B | 926.8B | 6.0% | 943.6B |
| EPS (IDR) | 39.13 | 19.20 | 22.28 | -24.5% | 14.85 |
| Shares | 3.3B | 3.3B | 3.3B | 0.0% | 3.3B |
| Debt | 267.2B | 323.2B | 325.6B | 10.4% | 88.4B |
| Equity | 675.6B | 659.4B | 666.6B | -0.7% | — |
| Op CF | 222.9B | 143.3B | 173.4B | -11.8% | 131.2B |
| Inv CF | -201.3B | -153.9B | -102.3B | — | — |
| Fin CF | -9.0B | -34.1B | -97.2B | — | — |
Not enough steady price history for a read yet.
How this is worked out
StockRank weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of JECX.JK are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| JECX.JK | PT Nitrasanata Dharma(you) | $244M | 33 | Sell |
| SAME.JK | PT Sarana Meditama Metropolitan Tbk | $262M | 40 | Hold |
| LPKR.JK | PT Lippo Karawaci Tbk | $169M | 31 | Sell |
| HEAL.JK | PT Medikaloka Hermina Tbk | $427M | 48 | Hold |
| CARE.JK | PT Metro Healthcare Indonesia Tbk | $682M | 17 | Strong Sell |
| BMHS.JK | PT Bundamedik Tbk | $95M | 61 | Hold |
| SILO.JK | PT Siloam International Hospitals Tbk | $1.3B | 75 | Buy |
| MIKA.JK | PT Mitra Keluarga Karyasehat Tbk | $1.1B | 82 | Strong Buy |
| SRAJ.JK | PT Sejahteraraya Anugrahjaya Tbk | $9.2B | 12 | Strong Sell |
| KAEF.JK | PT Kimia Farma Tbk | $115M | 30 | Sell |
Peer medians: ROE 9.2% · P/E 13.0x · Gross margin 35.8%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.